ProQR Therapeutics (NASDAQ:PRQR), a Leiden, Netherlands-based clinical-stage biotechnology company developing RNA-based therapies for severe genetic rare diseases, on Thursday reported a net loss of $9.1 million for its fourth quarter ended December 31, 2025.
Burning Rock Biotech (NASDAQ:BNR) on Thursday reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing modest top-line growth alongside significant margin expansion and cost discipline in its precision oncology testing business.
Seres Therapeutics (NASDAQ:MCRB) delivered a rare profitable year in 2025, though the black ink was the result of a major divestiture rather than a surge in drug sales.
Harvard Bioscience (NASDAQ:HBIO) posted a heavy net loss for fiscal 2025, a result dominated by a one-time accounting charge that overshadowed a year of steady operational progress in its core specialized laboratory equipment business.
Village Farms International (NASDAQ:VFF) cemented its transition from a traditional greenhouse grower to a high-margin cannabis producer, reporting record consolidated net income of $21 million, or $0.19 per share, for the full year 2025.
Pharming Group (NASDAQ:PHAR) reported a significant shift in its financial trajectory for the full year 2025, posting total revenues of $376.1 million, a 27% increase over the previous year.
REGENXBIO (NASDAQ:RGNX) shared positive interim data from its Phase I/II AFFINITY DUCHENNE trial on Wednesday, bolstering the case for its gene therapy candidate, RGX-202.
CVS Health's (NYSE:CVS) insurance unit, Aetna, has agreed to pay $117.7 million to resolve allegations that it defrauded the U.S. government by submitting inaccurate diagnosis codes for Medicare Advantage enrollees.
Citius Oncology (NASDAQ:CTOR) reported positive topline results on Tuesday from an investigator-initiated Phase 1 clinical trial evaluating its flagship immunotherapy, LYMPHIR (denileukin diftitox-cxdl), in combination with Merck’s pembrolizumab (Keytruda).
Quoin Pharmaceuticals (NASDAQ:QNRX) announced on Wednesday that the U.S. Food and Drug Administration has granted Fast Track Designation to its QRX003 lotion (4%), a topical therapy aimed at treating Netherton Syndrome.
Minerva Neurosciences (NASDAQ:NERV), a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, reported a net loss of $283.7 million for the fourth quarter ended December 31, 2025.
Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology-focused therapeutics company, reported financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday.
